Erik Zabel’s EPO Admissions and the Professional Consequences

On May 24, 2007, Erik Zabel admitted using EPO during the 1996 Tour de France. He said he stopped after roughly one week because of side effects. The confession converted a private history into a public account, but it did not begin the chronology. On April 27, 1994, Zabel had already tested positive for clostebol metabolites at Veenendaal–Veenendaal, placing a banned substance in his official anti-doping history years before he described the EPO episode.

The 1994 positive and the 2007 confession belonged to different evidentiary categories. The first was a recorded test result for clostebol metabolites. The second was Zabel’s own public statement about EPO during the Tour. Together they established a sequence that could not be reduced to a single television appearance: a positive test came first, then an admission of deliberate use during one of cycling’s most demanding races.

That May 24 confession widened within hours. Zabel and Rolf Aldag appeared on German television and confessed to using EPO while riding for Team Telekom. Aldag had been Zabel’s teammate, and his statement placed the practice inside the team’s competitive environment rather than outside it. Zabel’s account of stopping after a week remained the narrow version of his personal use, but the joint confession attached both riders to a wider Telekom-era doping history.

The doctors’ statements supplied the operational link. Former Team Telekom doctors Andreas Schmid and Lothar Heinrich said they had provided banned substances to riders, including EPO. Their admissions described access controlled by medical staff, not merely an athlete acting alone with an unknown supply. In that arrangement, a substance developed for medical use became part of the preparation available to professional cyclists competing for selection, results, and continued employment.

The disclosures altered the role of the team itself. Zabel’s confession identified his conduct; Aldag’s placed a teammate beside him; Schmid and Heinrich described doctors who supplied prohibited substances. Each statement occupied a different position in the chain. The cyclist used the drug. The teammate confirmed the practice. The doctors described how riders could obtain it. The public reckoning therefore moved beyond an isolated breach and toward the conditions in which doping could be organized.

For six years, the 2007 version remained the central public account of Zabel’s use: EPO during the 1996 Tour, followed by an early withdrawal after side effects. In 2013, that account expanded. On July 30, a report from Berlin said Zabel acknowledged using EPO, cortisone, and blood doping from 1996 until 2003. The new admission extended the period from about one week to seven years and added two other methods of prohibited enhancement.

The change was not a minor correction to a fixed story. It replaced a short episode with a sustained period covering multiple seasons of professional racing. EPO, cortisone, and blood doping carried different uses and procedures, but Zabel’s later statement grouped them within the same span, from 1996 through 2003. His public history now reached across the years in which he remained an elite rider and built the professional standing that later allowed him to work inside the sport.

Katusha responded to the broader admission by suspending Zabel. The suspension imposed a direct employment consequence on a former rider who had continued into team staff work. It also showed how a confession made years after the conduct could still affect a current professional relationship. The relevant decision was not a race ruling or a laboratory retest. It was a team’s choice to remove Zabel from active association after he acknowledged prolonged use of banned substances.

The consequences reached beyond Katusha. Zabel resigned his post on the Professional Cycling Council after the 2013 admission. That position placed him within cycling governance, where former competitors could influence or represent the sport after racing. His resignation removed that institutional role as the broader account became public. The sequence was precise: an expanded admission, a team suspension, and a departure from a council responsible for the sport’s professional affairs.

Zabel’s case therefore ended not with one test result or one confession, but with a changing account and the decisions that followed it. The 1994 clostebol positive anchored his name in the anti-doping record. The 2007 television confession acknowledged EPO use during the 1996 Tour and connected him with Aldag and two former Telekom doctors. The 2013 admission extended the use through 2003 and named cortisone and blood doping. Katusha suspended him, and the Professional Cycling Council lost his membership.